Sign in
4

Changes in Ownership

ArriVent BioPharma, Inc. Filed Acc 0001104659-24-102146

Chief Operating Officer acquired 27,566 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

LaChapelle Robin · Chief Operating Officer

Table I: Non-derivative

5 lines
Date Transaction Shares Price Value Owned after D/I
2024-09-19 Exercise or conversion : show line 1 in the form +2,700 $6.24 $16,848 99,717 D
2024-09-19 Exercise or conversion : show line 2 in the form +2,867 $2.28 $6,537 102,584 D
2024-09-19 Exercise or conversion : show line 3 in the form +7,164 $2.28 $16,334 109,748 D
2024-09-19 Exercise or conversion : show line 4 in the form +2,471 $2.28 $5,634 112,219 D
2024-09-19 Exercise or conversion : show line 5 in the form +12,364 $3.65 $45,129 124,583 D

Table II: Derivative

5 lines
Date Transaction Shares Owned after D/I
2024-09-19 Exercise or conversion : show line 6 in the form Stock Option (right to buy) −2,471 2,460 D
2024-09-19 Exercise or conversion : show line 7 in the form Stock Option (right to buy) −2,867 22,637 D
2024-09-19 Exercise or conversion : show line 8 in the form Stock Option (right to buy) −7,164 15,473 D
2024-09-19 Exercise or conversion : show line 9 in the form Stock Option (right to buy) −12,364 18,865 D
2024-09-19 Exercise or conversion : show line 10 in the form Stock Option (right to buy) −2,700 56,471 D
Loading xslF345X05/tm2424588-1_4seq1.xml…